American Trial Using Tranexamic Acid in Thrombocytopenia
Status:
Completed
Trial end date:
2020-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with
tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to
primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy.